BAP1 in solid tumors

被引：20

作者：

Di Nunno, Vincenzo ^{[1
]}

Frega, Giorgio ^{[2
]}

Santoni, Matteo ^{[3
]}

Gatto, Lidia ^{[2
]}

Fiorentino, Michelangelo ^{[4
]}

Montironi, Rodolfo ^{[5
]}

Battelli, Nicola ^{[3
]}

Brandi, Giovanni ^{[2
]}

Massari, Francesco ^{[1
]}

机构：

[1] St Orsola Marcello Malpighi Hosp, Div Oncol, Bologna, Italy

[2] Univ Bologna, St Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Oncol Unit, Bologna, Italy

[3] Macerata Hosp, Dept Oncol, Macerata, Italy

[4] St Orsola Marcello Malpighi Hosp, Addarii Inst Oncol, Pathol Serv, Bologna, Italy

[5] Polytech Univ Marche Reg, Sch Med, Sect Pathol Anat, United Hosp, Ancona, Italy

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 18期

关键词：

BAP1; cholangiocarcinoma; melanoma; mesothelioma; renal cell carcinoma; thymic carcinoma; HISTONE DEACETYLASE INHIBITOR; RENAL-CELL CARCINOMA; BRCA1-ASSOCIATED PROTEIN-1; INTRAHEPATIC CHOLANGIOCARCINOMA; MUTATIONS PREDISPOSE; PHASE-II; MESOTHELIOMA; ASBESTOS; CANCER; DIAGNOSIS;

D O I：

10.2217/fon-2018-0915

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

One of the most attractive cancer-related genes under investigation is BAP1. Reasons of this growing interest are related to the wide spectrum of pathways directly or indirectly modulated by this gene and shared by several solid tumors. Programmed cell-death, cell metabolisms, immune cells development, ferroptosis and defects in DNA damage response are only some of the multitude of processes depending on BAP1. Loss of this gene seems to occur in different times of tumor history. Moreover, times of BAP1 loss strongly diverge among primary tumors suggesting the presence of several and different triggering factors. Regardless of when it happens, BAP1 loss usually results in prognosis worsening and in the acquisition of more aggressive clinical features by cancer cells.

引用

页码：2151 / 2162

页数：12

共 50 条

[31] A spectrum of BAP1 expression from naevus to melanoma in a patient with BAP1 tumour predisposition syndrome
Ogura, Yasuaki
Shimauchi, Takatoshi
Sugiyama, Tomoko
Sugimura, Yuki
Nakagawa, Masahiro
Osawa, Harumo
Kojima, Risa
Iwaizumi, Moriya
Honda, Tetsuya
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2025,
[32] BAP1 mutations in uveal melanoma
Koopmans, Anna
Verdijk, Robert
van den Bosch, Thierry
van den Berg, Mike
Vaarwater, Jolanda
Paridaens, Dion
Kilic, Emine
de Klein, Annelies
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
[33] REGULATORY MECHANISMS OF THE DEUBIQUITINASE BAP1
Uriarte, Maxime
Daou, Salima
Barbour, Haithem
Ahmed, Oumamai
Masclef, Louis
Baril, Caroline
Sen Nkwe, Nadine
Bonneil, Eric
Ceccarelli, Derek
Masson, Jean-Yves
Thibault, Pierre
Sicheri, Frank
Yang, Haining
Carbone, Michele
Therrien, Marc
Affar, El Bachir
PROTEIN SCIENCE, 2019, 28 : 207 - 207
[34] Occurrence of BAP1 mutations in families
Luyten, G.
Chau, C.
Marinkovic, M.
Bleeker, J. C.
Jager, M. J.
de Klein, A.
Van Doorn, R.
Nielsen, M.
ACTA OPHTHALMOLOGICA, 2018, 96 : 76 - 76
[35] Clinical Implementation of BAP1 Inhibitors
Baas, P.
Schunselaar, L.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S305 - S306
[36] Screening for BAP1 in Danish Families
Wadt, Karin
Aoude, Lauren
Hayward, NicholasK.
Gerdes, Anne-Marie
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S101 - S102
[37] BAP1 and Breast Cancer Risk
Isabelle Coupier
Pierre-Yves Cousin
David Hughes
Patricia Legoix-Né
Alexandra Trehin
Olga M. Sinilnikova
Dominique Stoppa-Lyonnet
Familial Cancer, 2005, 4 : 273 - 277
[38] BAP1 loss of protein expression: an analysis for BAP1 germline Variants of Unknown Signification (VUS) interpretation
Cabaret, O.
Caillot, C.
Fenouil, T.
Soufir, N.
Bressac-de Paillerets, B.
de la Fouchardiere, A.
EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1538 - 1538
[39] Multiple BAP1 inactivated Naevi: sentinel markers of suspected germline BAP1 mutated cancer family
Nestor, L.
Aird, J.
Coleman, R.
Ormond, P.
Leonard, N.
Healy, C.
Calonje, E.
Gallagher, D.
Kelleher, F.
McMenamin, M.
BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 : 23 - 23
[40] Familial mesothelioma: Beyond BAP1
Cheung, Mitchell
Ohar, Jill A.
Howard, Suzanne E.
Howard, Timothy D.
Hesdorffer, Mary
Testa, Joseph R.
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →